|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/16/12 BioRestorative Therapies, Inc. 10-K 12/31/11 46:4.4M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 667K
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 12K
3: EX-3.2 Articles of Incorporation/Organization or Bylaws HTML 28K
5: EX-10.13 Material Contract HTML 18K
6: EX-10.17 Material Contract HTML 16K
7: EX-10.27 Material Contract HTML 17K
4: EX-10.4 Material Contract HTML 20K
8: EX-10.44 Material Contract HTML 316K
9: EX-10.45 Material Contract HTML 19K
10: EX-10.46 Material Contract HTML 29K
11: EX-10.47 Material Contract HTML 27K
12: EX-10.48 Material Contract HTML 27K
13: EX-10.49 Material Contract HTML 27K
14: EX-10.50 Material Contract HTML 26K
15: EX-10.51 Material Contract HTML 27K
16: EX-10.52 Material Contract HTML 98K
17: EX-14 Code of Ethics HTML 21K
18: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
19: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
20: EX-32 Certification -- §906 - SOA'02 HTML 15K
36: R1 Document and Entity Information HTML 45K
30: R2 Consolidated Balance Sheets HTML 91K
34: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
37: R4 Consolidated Statements of Operations HTML 71K
44: R5 Consolidated Statements of Changes in HTML 164K
Stockholders' Deficiency
31: R6 Consolidated Statements of Changes in HTML 57K
Stockholders' Deficiency (Parenthetical)
33: R7 Consolidated Statements of Cash Flows HTML 141K
29: R8 Business Organization and Nature of Operations HTML 26K
27: R9 Going Concern and Management Plans HTML 18K
45: R10 Summary of Significant Accounting Policies HTML 39K
39: R11 Property and Equipment HTML 23K
38: R12 Accrued Expenses and Other Liabilities HTML 19K
41: R13 Notes Payable HTML 24K
42: R14 Income Taxes HTML 39K
40: R15 Commitments and Contingencies HTML 61K
43: R16 Stockholders' Deficiency HTML 95K
35: R17 Subsequent Events HTML 30K
46: XML IDEA XML File -- Filing Summary XML 43K
28: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 325K
21: EX-101.INS XBRL Instance -- brtx-20111231 XML 681K
23: EX-101.CAL XBRL Calculations -- brtx-20111231_cal XML 94K
24: EX-101.DEF XBRL Definitions -- brtx-20111231_def XML 330K
25: EX-101.LAB XBRL Labels -- brtx-20111231_lab XML 464K
26: EX-101.PRE XBRL Presentations -- brtx-20111231_pre XML 371K
22: EX-101.SCH XBRL Schema -- brtx-20111231 XSD 66K
32: ZIP XBRL Zipped Folder -- 0001144204-12-021914-xbrl Zip 72K
EXHIBIT 14
BIORESTORATIVE THERAPIES, INC.
Code of Ethics
Introduction
This Code of Ethics (the “Code”) embodies the commitment of BioRestorative Therapies, Inc. and its subsidiaries (collectively, the “Company”) to conduct its business in accordance with all applicable laws, rules and regulations and the highest ethical standards. All directors, officers and employees of the Company (individually, a “Covered Party” and collectively, the “Covered Parties”) are expected to adhere to the principles and procedures set forth in this Code. For purposes of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder, this Code shall be the Company’s code of ethics for its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.
Code Compliance and Reporting
The Covered Parties should strive to identify and raise potential issues before they lead to problems, and should ask about the application of this Code whenever in doubt. Any Covered Party who becomes aware of any existing or potential violation of this Code should promptly notify the Audit Committee of the Board of Directors (see Exhibit A attached hereto for contact information) (we refer to such contacts as the “Appropriate Ethics Contact”). The Company will take such disciplinary or preventive action as it deems appropriate to address any existing or potential violation of this Code brought to its attention.
Any questions relating to how these policies should be interpreted or applied should be addressed to the Appropriate Ethics Contact.
Personal Conflicts of Interest
A “personal conflict of interest” occurs when an individual's private interest improperly interferes with the interests of the Company. Personal conflicts of interest, whether actual or apparent, are prohibited as a matter of Company policy, unless they have been approved or waived by the Company. In particular, a Covered Party must never use or attempt to use his or her position at the Company to obtain any improper personal benefit for himself or herself, for his or her family members, or for any other person, including loans or guarantees of obligations, from any person or entity.
Service to the Company should never be subordinated to personal gain and advantage. Conflicts of interest, whether actual or apparent, should, to the extent possible, be avoided.
Any Covered Party who is aware of a material transaction or relationship that could reasonably be expected to give rise to a conflict of interest should discuss the matter promptly with the Appropriate Ethics Contact.
C:
Public Disclosure
It is Company policy that the information in our public communications, including our filings made with the United States Securities and Exchange Commission, be full, fair, accurate, timely and understandable. Covered Parties who are involved in the Company’s disclosure process are responsible for acting in furtherance of this policy. In particular, these individuals are required to maintain familiarity with the disclosure requirements applicable to the Company and are prohibited from knowingly misrepresenting, omitting, or causing others to misrepresent or omit, material facts about the Company to others, whether within or outside the Company, including the Company's independent auditors.
Compliance with Laws, Rules and Regulations
It is Company policy to comply with all applicable laws, rules and regulations. It is the personal responsibility of each Covered Party to adhere to the standards and restrictions imposed by those laws, rules and regulations. If a Covered Party is not aware or familiar with the laws, rules or regulations that apply specifically to the Company’s business, he or she must request that the Appropriate Ethics Contact provide such information.
Generally, it is both illegal and against Company policy for any Covered Party who is aware of material nonpublic information relating to the Company, any of the Company's business associates or any other private or governmental issuer of securities to buy or sell any securities of those issuers, or recommend that another person buy, sell or hold the securities of those issuers. Any Covered Party who is uncertain about the legal rules involving his or her purchase or sale of any Company securities or any securities in issuers with which he or she is familiar by virtue of his or her work for the Company should consult with the Appropriate Ethics Contact before making any such purchase or sale.
Amendment, Modification and Waiver
This Code may be amended or modified by our Board of Directors. Waivers of this Code may only be granted by the Board of Directors or a committee of the Board with specific delegated authority. Waivers will be disclosed as required by the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder and any applicable rules relating to the maintenance of the listing of the Company’s securities on any stock exchange.
C:
EXHIBIT A
Appropriate Ethics Contact
BioRestorative Therapies, Inc. Audit Committee
BioRestorative Therapies, Inc.
555 Heritage Drive
Suite 130
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/24 BioRestorative Therapies, Inc. S-1/A 1:86K Certilman Balin … LLP/FA 4/01/24 BioRestorative Therapies, Inc. 10-K 12/31/23 80:9M M2 Compliance LLC/FA 3/27/23 BioRestorative Therapies, Inc. 10-K 12/31/22 79:7.4M M2 Compliance LLC/FA 3/30/22 BioRestorative Therapies, Inc. 10-K 12/31/21 92:16M M2 Compliance LLC/FA 11/04/21 BioRestorative Therapies, Inc. S-1/A 84:16M M2 Compliance LLC/FA 10/29/21 BioRestorative Therapies, Inc. S-1/A 83:15M M2 Compliance LLC/FA 10/18/21 BioRestorative Therapies, Inc. S-1/A 10/15/21 82:15M M2 Compliance LLC/FA 8/06/21 BioRestorative Therapies, Inc. S-1 8/09/21 2:3.3M M2 Compliance LLC/FA 4/30/21 BioRestorative Therapies, Inc. 10-K 12/31/20 76:7.1M M2 Compliance LLC/FA 3/18/21 BioRestorative Therapies, Inc. 10-K 12/31/19 81:8.9M M2 Compliance LLC/FA 10/19/12 SEC UPLOAD¶ 10/21/17 1:34K BioRestorative Therapies, Inc. |